Totals for Iatrogenic (doctor caused) Deaths
Caroline Chen of ProPublica has written a provocative article challenging the objectivity of the FDA in its approval of new drugs. Entitled: “FDA Repays Industry by Rushing Risky Drugs to Market”, Chen contends that the agency is beholden to the biopharmaceutical industry which pays three quarters of the FDA’s budget used for the drug review process. This is an astounding number. Is any other federal agency supported to this extent by the industry it regulates? Given this level of support, one might assume that the FDA would bend over backwards to meet the needs of its financial backers. Full article on ProPublica
An FDA testified to Congress that he warned his superiors at the FDA but they threatened him and did all they could to hide the data from the public.
The history of vaccine corporations reveals the commission of crimes and offences of the highest order.
MODERNA tested only 45 people in Phase 1 trials, then announced "positive results", then their CEO, executives, and Funds controlled by its Chairman of the Board sold $90 million of its shares.
Since January CEO Bansell sold roughly $ 40,000,000 of Moderna stock held by himself or controlled Funds.
Chief Medical officer Tal Zaks sold $60,000,000 President Hoge sold more than.$10,000,000 PFIZER tested fewer than 200 people in its Phase 1 trial. Pfizer CEO Bourla sold 62% of his stock for $6.500,000 the same day Pfizer announced their product was highly effective. As at December 2020 Bourla had not taken his Pfizer shot claiming he was 59 years old and in good health.
The vaxccine mobsters criminal record: The criminal record of fines and penalties of the convicted killing and maiming mobsters:
Johnson and Johnson $4,200,000,000
Pfizer $4,248,447,763 including $558,705,368 under the False Claims Act
AstraZeneca $1,100,000,000
Gullible and impotent politicians outmaneuvered by the Big Pharma mobsters. Enjoy your decisions folks because you will ultimately own them. -Sami Elmas
by Caroline Chen, June 2018
As pharma companies underwrite three-fourths of the FDA’s budget for scientific reviews, the agency is increasingly fast-tracking expensive drugs with significant side effects and unproven health benefits.
Nevertheless, the U.S. Food and Drug Administration approved both of these drugs — with a deadly aftermath. Uloric’s manufacturer reported last November that patients on the drug were 34 percent more likely to die from heart disease than people taking an alternative gout medication. And since the FDA fast-tracked approval of Nuplazid and it went on the market in 2016 at a price of $24,000 a year, there have been 6,800 reports of adverse events for patients on the drug, including 887 deaths as of this past March 31.
The FDA is increasingly green-lighting expensive drugs despite dangerous or little-known side effects and inconclusive evidence that they curb or cure disease. Once widely assailed for moving slowly, today the FDA reviews and approves drugs faster than any other regulatory agency in the world. Between 2011 and 2015, the FDA reviewed new drug applications more than 60 days faster on average than did the European Medicines Agency.
“Instead of a regulator and a regulated industry, we now have a partnership,” said Dr. Michael Carome, director of the health research group for the nonprofit advocacy organization Public Citizen, and a former U.S. Department of Health and Human Services official. “That relationship has tilted the agency away from a public health perspective to an industry friendly perspective.”
While the FDA over the past three decades has implemented at least four major routes to faster approvals — the current commissioner, Dr. Scott Gottlieb, is easing even more drugs’ path to market. More